Altavant Sciences
Innovative therapies targeting serotonin pathways for pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and sarcoidosis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Related Content
Altavant Sciences is a biopharmaceutical company focused on developing innovative therapies for serious pulmonary diseases. The company's lead candidate, rodatristat ethyl, is a prodrug designed to inhibit tryptophan hydroxylase (TPH), thereby blocking peripheral serotonin production. This mechanism is aimed at treating diseases characterized by pathological serotonin signaling, such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), and sarcoidosis.
Altavant operates in the biopharmaceutical market, primarily targeting healthcare providers and patients suffering from these severe conditions. The business model revolves around the research, development, and commercialization of novel therapeutic agents. Revenue is generated through the successful development and eventual sale or licensing of these therapies.
The company leverages its expertise in biotech, big pharma, and venture capital to navigate the complex landscape of drug development and regulatory approval. With a strong focus on clinical trials and data-driven results, Altavant aims to bring effective treatments to market, thereby addressing unmet medical needs.
Keywords: biopharmaceutical, serotonin pathways, pulmonary diseases, rodatristat ethyl, tryptophan hydroxylase, PAH, IPF, sarcoidosis, clinical trials, innovative therapies.